C
Caliber Therapeutics
Innovative bioelectronic therapies for hypertension and cardiovascular health
About Caliber Therapeutics
Caliber Therapeutics specializes in developing advanced bioelectronic therapies aimed at treating hypertension and improving cardiovascular health. The company operates in the medical device market, focusing on patients who require pacemakers and other cardiovascular interventions. Caliber Therapeutics' flagship product, BackBeat Cardiac Neuromodulation, is a programmable and adjustable therapy delivered via an implantable cardiac pulse generator. This device has shown significant success in reducing 24-hour ambulatory systolic blood pressure in patients with persistent hypertension. The business model revolves around the development, clinical testing, and commercialization of these innovative medical devices. Revenue is generated through the sale of these devices to healthcare providers and institutions. The company serves a niche market of elderly patients with cardiovascular conditions, particularly those indicated for pacemaker implantation.
Source: Dealroom company dataAt a glance
- Founded
- 2005
- Headquarters
- New Hope, United States
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
SternAegis Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Caliber Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Caliber Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.